Rein Therapeutics, Inc. (RNTX) Form 10-Q — May 15, 2026
Rein Therapeutics (RNTX) completed a $57.5 million underwritten public offering in May 2026, raising $53.1 million in net proceeds after deducting underwriting discounts and expenses. The company sold 57.5 million shares of common stock at a public offering price of $1.00 per share, including the full exercise of the underwriters' 45-day over-allotment option. Management stated that the net proceeds, combined with existing cash of $4.4 million as of March 31, 2026, will fund operations into the first quarter of 2028. This capital is specifically intended to support the completion of the Phase 2 RENEW clinical trial for its lead candidate, LTI-03, which targets idiopathic pulmonary fibrosis.
Key figures
- Total Debt
- 4923000
- Total Assets
- 26288000
- Cash Position
- 4445000
- Gross Proceeds
- 57500000
- Offering Price
- 1
- Shares Offered
- 57500000
- Shares Outstanding
- 85539032
- Cash Runway
- Q1 2028
- Ga Expense Q1
- 2157000
- Rd Expense Q1
- 3073000
- Net Proceeds May2026
- 53106000
Price after filing
Close on the filing date to close N calendar days later (from $1.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.